within Pharmacolibrary.Drugs.ATC.N;

model N07XX23
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0005833333333333334,
    adminDuration  = 600,
    adminMass      = 140 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.08,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX23</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Troriluzole is a prodrug of riluzole, an investigational agent designed to modulate glutamatergic neurotransmission. It is under development primarily for neurological and neuropsychiatric disorders including Alzheimer's disease, spinocerebellar ataxia, and obsessive-compulsive disorder. Troriluzole is not currently approved for medical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in healthy adults based on prodrug characteristics and limited clinical summary data available from secondary sources.</p><h4>References</h4><ol><li><p>Silk, AW, et al., &amp; Malhotra, J (2022). A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. <i>European journal of medical research</i> 27(1) 107–None. DOI:<a href=&quot;https://doi.org/10.1186/s40001-022-00732-w&quot;>10.1186/s40001-022-00732-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35780243/&quot;>https://pubmed.ncbi.nlm.nih.gov/35780243</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX23;
